von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction

Heart

Volumn 80, Issue 4, 1998, Pages 334-337

  Jansson, J H ^a   Nilsson, T K ^b   Johnson, O ^b  

^a Skelleftea Hospital   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dehydroepiandrosterone sulphate; Fibrinolysis; Myocardial infarction; Plasminogen activator inhibitor; Risk factors; Tissue plasminogen activator; von Willebrand factor

Indexed keywords

PRASTERONE SULFATE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTOR; VEIN OCCLUSION;

EID: 0031679528     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.4.334     Document Type: Article

References (29)

1. Hamsten A, Wiman B, De Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
2. Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987;48: 621-30.
3. Hamsten A, DeFaire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii:3-9.
4. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-61.
5. Jansson J H, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
6. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arteriosclerosis and Thrombosis 1992;12:1063-70.
7. Korninger C, Lechner K, Niessner H, et al. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984:52:127-30.
8. Haines AP, Howarth D, North WRS, et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983;50:800-3.
9. Thompson GS, Kienast J, Pyke S, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
10. Brännström M, Jansson JH, Boman K, et al. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost 1995;74:612-15.
11. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park heart study. Lancet 1986;ii:533-7.
12. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
13. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park heart study. Lancet 1993;342:1076-79.
14. Lopez-S, A. Metabolic and endocrine factors in ageing. In: Rothschild H, Chapman, CF, eds. Risk factors for senility. New York: Oxford University Press, 1984:205.
15. Ben-David M, Dikstein S, Bismuth G, et al. Antihypercholesterolemic effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 1967;125:11-36.
16. Coleman DL, Leiter EH, Schwitzer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982;31:830.
17. Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis. Acta Chir Scand 1985;151:515-19.
18. Mellbring G, Chotai J, Nilsson TK. Preoperative plasma dehydroepiandrosterone sulphate concentrations in relation to postoperative deep vein thrombosis after major abdominal surgery. Surgical Research Communications 1989; 6:29-34.
19. Mitchell LE, Sprecher DL, Borecki IB, et al. Evidence for an association between dehydroepiandrosterone sulphate and nonfatal, premature myocardial infarction in males. Circulation 1994;89:89-93.
20. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman, et al. Decreased plasma dehydroepiandrosterone sulphate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 1989;79:197-203.
21. Barret-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrostenedione sulfate, mortality, and cardiovascular disease. N Engl J Med 1986;315:1519-24.
22. de Faire U, Friberg L, Lorich U, et al. A validation of cause-of-death certification in 1156 deaths. Acta Med Scand 1976;200:223-8.
23. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc 1972;4:187-220.
24. Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulphate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990;16:862-70.
25. Contoreggi CS, Blackman MR, Andres R, et al. Plasma levels of estradiol, testosterone and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990;11:460-70.
26. LaCroix AZ, Yano K, Reed D. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992;86:1529-32.
27. Gralnick HR, Williams SB, Mc Keown LP, et al. Platelet von Willebrand factor. Mayo Clinics Proceedings 1991;66:634-40.
28. Bowie EJW. The role of von Willebrand factor in thrombosis. In: Poller L, Tompson JM, eds. Thrombosis and its management. Edinburgh: Churchill Livingstone, 1993: 134-10.
29. Scandinavian Simvastatin Survival Group. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-5.